Wells Fargo & Company Trims CF Industries (NYSE:CF) Target Price to $83.00

CF Industries (NYSE:CF) had its price target cut by analysts at Wells Fargo & Company from $87.00 to $83.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage currently has an “overweight” rating on the basic materials company’s stock. Wells Fargo & Company‘s price objective indicates a potential upside of 13.90% from the company’s previous close.

A number of other research analysts have also weighed in on the company. BMO Capital Markets cut their price objective on CF Industries from $100.00 to $95.00 and set an “outperform” rating for the company in a research report on Monday, May 6th. Berenberg Bank raised their price target on CF Industries from $68.00 to $69.00 and gave the company a “hold” rating in a report on Wednesday, April 17th. UBS Group decreased their price objective on CF Industries from $86.00 to $78.00 and set a “neutral” rating on the stock in a report on Tuesday, July 9th. Scotiabank cut their target price on shares of CF Industries from $86.00 to $80.00 and set a “sector perform” rating for the company in a report on Monday, May 6th. Finally, Royal Bank of Canada decreased their price target on shares of CF Industries from $90.00 to $85.00 and set an “outperform” rating on the stock in a research note on Monday. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $83.19.

CF Industries Stock Down 0.5 %

Shares of CF opened at $72.87 on Tuesday. The business’s 50 day moving average is $74.87 and its 200 day moving average is $77.94. The company has a current ratio of 3.94, a quick ratio of 3.55 and a debt-to-equity ratio of 0.37. CF Industries has a 12-month low of $69.13 and a 12-month high of $87.90. The company has a market capitalization of $13.32 billion, a PE ratio of 12.10, a price-to-earnings-growth ratio of 2.27 and a beta of 0.95.

CF Industries (NYSE:CF) last released its earnings results on Wednesday, May 1st. The basic materials company reported $1.03 EPS for the quarter, missing the consensus estimate of $1.47 by ($0.44). The company had revenue of $1.47 billion during the quarter, compared to analysts’ expectations of $1.46 billion. CF Industries had a return on equity of 14.08% and a net margin of 19.03%. CF Industries’s quarterly revenue was down 26.9% compared to the same quarter last year. During the same period last year, the firm posted $2.85 EPS. Research analysts expect that CF Industries will post 5.19 earnings per share for the current fiscal year.

Institutional Trading of CF Industries

Several institutional investors and hedge funds have recently made changes to their positions in the business. Westside Investment Management Inc. bought a new stake in CF Industries during the 1st quarter valued at about $25,000. Turtle Creek Wealth Advisors LLC bought a new stake in shares of CF Industries during the fourth quarter valued at approximately $29,000. Bruce G. Allen Investments LLC purchased a new stake in shares of CF Industries in the fourth quarter valued at approximately $32,000. Meeder Asset Management Inc. bought a new position in CF Industries in the fourth quarter worth approximately $36,000. Finally, ORG Partners LLC increased its holdings in CF Industries by 62.2% during the 4th quarter. ORG Partners LLC now owns 600 shares of the basic materials company’s stock worth $48,000 after purchasing an additional 230 shares during the period. 93.06% of the stock is currently owned by institutional investors.

About CF Industries

CF Industries Holdings, Inc, together with its subsidiaries, engages in the manufacture and sale of hydrogen and nitrogen products for energy, fertilizer, emissions abatement, and other industrial activities in North America, Europe, and internationally. It operates through Ammonia, Granular Urea, UAN, AN, and Other segments.